ArticleFrontiers in immunology2022
FoxP3
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Excessive reactive oxygen species attenuated IL-17 production in CD161Cell communication and signaling : CCS · 2026Article
- Mucosal immunity in acute HIV: a review of recent work.Current opinion in HIV and AIDS · 2025Review
- CD39Frontiers in oncology · 2025Review
- Double, double toil and trouble: transforming growth factor beta (TGF-β) in HIV infection.Frontiers in immunology · 2025Review
- Article
- Case report: Bullous pemphigoid in HIV-1-positive patients: interplay or coincidence? A case series and review of the literature.Frontiers in immunology · 2023Review
- Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Besides CD4 regulatory T-cells (Tregs), immunosuppressor FoxP3 Methods: Subsets of FoxP3 Results: Acute and chronic infection were associated with increased total, effector memory, and terminally differentiated FoxP3 Conclusions: Although early ART normalized total FoxP3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.